These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Re: Cesare Cozzarini, Claudio Fiorino, Chiara Deantoni, et al. Higher-than-expected severe (grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur urol 2014;66:1024-30. De Bari B; Alongi F; Arcangeli S Eur Urol; 2014 Dec; 66(6):e111-2. PubMed ID: 25190611 [No Abstract] [Full Text] [Related]
5. Re:Mark K. Buyyounouski. Radiobiological modeling and the study of hypofractionated radiotherapy for prostate cancer. Eur Urol 2014;66:1031-2. Fiorino C; Briganti A; Cozzarini C Eur Urol; 2015 Mar; 67(3):e56-7. PubMed ID: 25466947 [No Abstract] [Full Text] [Related]
6. [Acute toxicity after hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer]. Lohr F; Ehmann M Strahlenther Onkol; 2016 Jan; 192(1):67-9. PubMed ID: 26545765 [No Abstract] [Full Text] [Related]
7. Reply to Berardino De Bari, Filippo Alongi, Stefano Arcangeli's letter to the editor re: Cesare Cozzarini, Claudio Fiorino, Chiara Deantoni, et al. Higher-than-expected severe (grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur urol 2014;66:1024-30. Cozzarini C; Fiorino C; Briganti A; Montorsi F; Di Muzio N Eur Urol; 2014 Dec; 66(6):e113-4. PubMed ID: 25199719 [No Abstract] [Full Text] [Related]
8. Combination of IG-IMRT and permanent source prostate brachytherapy in patients with organ-confined prostate cancer: GU and GI toxicity and effect on erectile function. Valakh V; Kirichenko A; Miller R; Sunder T; Miller L; Fuhrer R Brachytherapy; 2011; 10(3):195-200. PubMed ID: 21030319 [TBL] [Abstract][Full Text] [Related]
9. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes. Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511 [TBL] [Abstract][Full Text] [Related]
10. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer. Fang P; Mick R; Deville C; Both S; Bekelman JE; Christodouleas JP; Guzzo TJ; Tochner Z; Hahn SM; Vapiwala N Cancer; 2015 Apr; 121(7):1118-27. PubMed ID: 25423899 [TBL] [Abstract][Full Text] [Related]
11. Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer. Alongi F; Cozzi L; Fogliata A; Iftode C; Comito T; Clivio A; Villa E; Lobefalo F; Navarria P; Reggiori G; Mancosu P; Clerici E; Tomatis S; Taverna G; Graziotti P; Scorsetti M Anticancer Res; 2013 Oct; 33(10):4537-43. PubMed ID: 24123027 [TBL] [Abstract][Full Text] [Related]
12. Re: Grace L. Lu-Yao, Peter C. Albertsen, Dirk F. Moore, Yong Lin, Robert S. DiPaola, Siu-Long Yao. Fifteen-year Outcomes Following Conservative Management Among Men aged 65 Years or Older with Localized Prostate Cancer. Eur Urol 2015;68:805-11. Froehner M; Koch R; Wirth MP Eur Urol; 2016 Jun; 69(6):e130. PubMed ID: 26683758 [No Abstract] [Full Text] [Related]
13. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287 [TBL] [Abstract][Full Text] [Related]
15. Image-guided radiation therapy based on helical tomotherapy in prostate cancer: minimizing toxicity. Acevedo-Henao CM; Lopez Guerra JL; Matute R; Puebla F; Russo M; Rivin E; Sanchez-Reyes A; Ortiz MJ; Azinovic I Oncol Res Treat; 2014; 37(6):324-30. PubMed ID: 24903763 [TBL] [Abstract][Full Text] [Related]
16. [Late effects following curative radiotherapy for prostate cancer]. Fokdal LU; Høyer M Ugeskr Laeger; 2005 Sep; 167(37):3502-7. PubMed ID: 16159460 [TBL] [Abstract][Full Text] [Related]
17. Comparison and limitations of DVH-based NTCP models derived from 3D-CRT and IMRT data for prediction of gastrointestinal toxicities in prostate cancer patients by using propensity score matched pair analysis. Troeller A; Yan D; Marina O; Schulze D; Alber M; Parodi K; Belka C; Söhn M Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):435-43. PubMed ID: 25636766 [TBL] [Abstract][Full Text] [Related]